References
- PelletierDHaferDAFingolimod for multiple sclerosisN Engl J Med201236633934722276823
- ConfavreuxCVukusicSNatural history of multiple sclerosis: a unifying conceptBrain200612960661616415308
- SadovnickADEbersGCWilsonRWPatyDWLife expectancy in patients attending multiple sclerosis clinicsNeurology1992429919941579256
- Brønnum-HansenHKoch-HenriksenNStenagerETrends in survival and cause of death in Danish patients with multiple sclerosisBrain200412784485014960501
- CompstonAColesAMultiple sclerosisLancet20083721502151718970977
- BoscaICoretFValeroCEffect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferonMult Scler20081463663918566027
- ElovaaraIEarly treatment in multiple sclerosisJ Neurol Sci2011311S24S28
- McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple SclerosisAnn Neurol20015012112711456302
- PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
- HutchinsonMKapposLCalabresiPThe efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELJ Neurol200925640541519308305
- Weinstock-GuttmanBGalettaSLGiovannoniGAdditional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSJ Neurol201225989890522008873
- TyasDKerriganJRussellNNixonRThe distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?Value Health20071038638917888103
- NaciHFleurenceRBirtJDuhigAEconomic burden of multiple sclerosis: a systematic review of the literaturePharmacoeconomics20102836337920402540
- BourdetteDNProchazkaAVMitchellWLicariPBurksJHealth care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study GroupArch Phys Med Rehabil19937426318420515
- O’BrienJAWardAJPatrickARCaroJCost of managing an episode of relapse in multiple sclerosis in the United StatesBMC Health Serv Res200331712952552
- PillMGilkinBMeasuring the impact of natalizumab therapy on health care utilization in a commercially managed multiple sclerosis population. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011Value Health201114A1A214
- PillMGilkinBEconomic trends associated with natalizumab therapy in a commercially managed multiple sclerosis population. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011Value Health201114A1A214
- ProsperiniLGianniCLeonardiLEscalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosisMult Scler201218647121828195
- Castillo-TrivinoTMowryEMGajofattoASwitching multiple sclerosis patients with breakthrough disease to second-line therapyPlos One20116e1666421304907
- GaniRGiovannoniGBatesDKemballBHughesSKerriganJCost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UKPharmacoeconomics20082661762718563952
- ChiaoEMeyerKCost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosisCurr Med Res Opin2009251445145419422279
- BakhshaiJBleu-LainéRJungMThe cost effectiveness and budget impact of natalizumab for formulary inclusionJ Med Econ201013636920028199
- O’DayKMeyerKMillerRMAgarwalSFranklinMCost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosisJ Med Econ20111461762721777161
- SharacJMcCronePSabes-FigueraRPharmacoeconomic considerations in the treatment of multiple sclerosisDrugs2010701677169120731475
- OwensGMOlveyELSkrepnekGHPillMWPerspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapiesJ Manag Care Pharm201319S41S5323383732
- RioJPorcelJTéllezNFactors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisMult Scler20051130630915957512
- O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler200511465015732266
- ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disabilityBrain20101331914192920534650